OPEN END TURBO OHNE STOP-LOSS - ASTRAZENECA | Market Closed - Bid/Ask 02:12:07 2024-07-04 EDT | Pre-market 02:06:07 | |||
| 5.58 EUR | -0.36% |
|
5.77 | +3.41% |
| Current month | -7.00% | ||
| 1 month | -6.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 5.58 | -0.36% |
| 24-07-03 | 5.6 | -3.61% |
| 24-07-02 | 5.81 | -3.65% |
| 24-07-01 | 6.03 | +0.50% |
| 24-06-28 | 6 | -0.99% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 02:12 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Lang & Schwarz |
| WKN | LX0DGB |
| ISIN | DE000LX0DGB6 |
| Date issued | 2021-03-17 |
| Strike | 87.38 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.43 € |
|---|---|
| Lowest since issue | 0.27 € |
| Spread | 0.2 € |
| Spread % | 3.41% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
154.5
USD
Average target price
174.6
USD
Spread / Average Target
+12.95%
- Stock Market
- Certificates
- Certificat
